07:37:11 EDT Tue 19 Mar 2024
Enter Symbol
or Name
USA
CA



Advanced Proteome Therapeutics Corp
Symbol APC
Shares Issued 160,020,766
Close 2018-04-23 C$ 0.05
Market Cap C$ 8,001,038
Recent Sedar Documents

Advanced Proteome appoints Bardia, Thurber as advisers

2018-04-24 10:00 ET - News Release

Dr. Allen Krantz reports

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF SCIENTIFIC ADVISORY BOARD MEMBERS

Advanced Proteome Therapeutics Corp. has appointed two new members to its scientific advisory board: Dr. Aditya Bardia, a board-certified medical oncologist, is an attending physician at Massachusetts General Hospital Cancer Center (MGHCC) at Harvard Medical School in Boston, and Dr. Greg Thurber is a member of the faculty of chemical engineering and biomedical engineering at the University of Michigan.

Dr. Bardia, director of the precision oncology program at the MGH Center for Breast Cancer, is active in areas which span the integration of precision diagnostics and precision therapeutics for significantly improving the outcomes of patients afflicted with breast cancer, to research in the evolving field of liquid biopsy for early cancer detection. He has been the principal investigator of several clinical trials related to novel therapies in breast cancer, including antibody-drug conjugates such as sacituzumab govitecan (given breakthrough designation status by the Federal Drug Administration in 2016). Dr. Bardia has been the recipient of numerous awards as well as being co-leader of the molecular and precision tumour board at MGHCC, and an editorial board member of the American Society of Clinical Oncology (ASCO) tumor board. Dr. Thurber's work involves applying fundamental biotransport principles to design novel therapeutics and molecular imaging agents, and developing an understanding of the critical factors that govern the distribution of agents, such as antibody-drug conjugates, in cells and tissues to optimize their efficacies. An important point of focus is the matter of compatibility among antibody, linker and toxin that comprise an ADC, which is central to the clinical success of this agent. Dr. Thurber, who has been a member of the junior faculty's radiology department at Harvard Medical School/Massachusetts General Hospital, has received several awards and is the recipient of a National Science Foundation Career award.

Dr. Krantz, the founder of the company, commented: "We are extremely fortunate to have Dr. Bardia and Dr. Thurber serve as members of the scientific advisory board in this phase of the company's development. Having their formidable knowledge and expertise bearing on the field of antibody-drug conjugates will certainly be an asset for us in the challenges that lie ahead, and are aligned with our objectives.

"Many thanks are also due to Dr. Stephen Hanessian and Dr. Steven Withers for serving on the scientific advisory board since the inception of the company, and making available their capabilities in the design and discovery of novel therapeutics."

About Advanced Proteome Therapeutics Corp.

Advanced Proteome is developing a proprietary technology to directly target cancerous tumours and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which, to date, has been extremely cumbersome, limiting their potential.

© 2024 Canjex Publishing Ltd. All rights reserved.